Skip to main content
S 543 118th Congress Senate Health Cardiovascular and respiratory health Drug safety, medical device, and laboratory regulation Drug therapy Health care quality Health facilities and institutions Health information and medical records Health promotion and preventive care Medical research Neurological disorders Research administration and funding

CCM–CARE Act of 2023

Introduced: February 28, 2023 Introduced by: Luján, Ben Ray Democratic · New Mexico See on congress.gov
Sign in to write a letter Sign in to watch
This bill died when the 118th Congress ended
It never became law before the 118th Congress (2023–2024) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Feb 28, 2023
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Feb 28, 2023
Introduced in Senate
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

Cerebral Cavernous Malformations Clinical Awareness, Research, and Education Act of 2023 or the CCM-CARE Act of 2023

This bill requires the National Institutes of Health (NIH) and other agencies to expand and coordinate their efforts to research cerebral cavernous malformation. (Cerebral cavernous malformation is a condition in which blood vessels in the brain and spinal cord become enlarged, which can lead to seizures, paralysis, hearing or vision loss, and bleeding in the brain.)

The NIH must (1) award grants for medical, clinical, and pharmacological research; (2) award grants to support a network of clinical research centers intended to develop a cure for the condition; and (3) convene a Cerebral Cavernous Malformations Research Consortium to develop programs for clinicians, scientists, and patients.

The Centers for Disease Control and Prevention must award grants to research entities for collecting and reporting data about cerebral cavernous malformation.

The Food and Drug Administration must accelerate the clinical trial process for cerebral cavernous malformation by supporting (1) appropriate laboratory indicators of the condition, (2) the qualification of clinical outcome measures related to quality of life, (3) investigational drug applications, and (4) expedited peer-review pathways.

What's happening now February 28, 2023

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
 Cosponsors 1
All 1 Democratic 1
D
Heinrich, Martin
New Mexico · Feb 28, 2023
Cite this page click to expand
APA
U.S. Congress. (2026). S. 543: CCM–CARE Act of 2023. 118th Congress. Open America. https://openamerica.io/bill/118-S-543/
MLA
"S. 543: CCM–CARE Act of 2023." 118th Congress, 2026, Open America, https://openamerica.io/bill/118-S-543/.
Bluebook (legal)
S. 543, 118th Cong. (2026), https://openamerica.io/bill/118-S-543/.
Markdown link
[S. 543: CCM–CARE Act of 2023](https://openamerica.io/bill/118-S-543/)
Report a problem